The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.